Escape Bio nabs $73m
Escape Bio, a developer of treatments for genetic neurodegenerative diseases, has raised $73 million in financing.
14 September 2020•1 min read
Escape Bio, a developer of treatments for genetic neurodegenerative diseases, has raised $73 million in financing.
Matter taps LPs that bring more than money for oversubscribed Fund II
28 October 2026 · 5 mins read
BackingMinds raises €50m for Fund III, focused on Nordic start-ups
26 October 2026 · 3 mins read
Singapore VC plants flag in Ohio in search of US investors
26 October 2026 · 6 mins read
New AI threats are fueling VC investment in cybersecurity
22 October 2026 · 4 mins read
Inspired Capital holds quick close on $450m for Fund IV
20 October 2026 · 4 mins read
Inovia hits $200m in first close for sixth early-stage fund
19 October 2026 · 4 mins read
San Joaquin County to slow venture commitments
15 October 2026 · 2 mins read
